CN102423468B - Chinese medicinal composition for resisting hepatic fibrosis and preparation method and use thereof - Google Patents
Chinese medicinal composition for resisting hepatic fibrosis and preparation method and use thereof Download PDFInfo
- Publication number
- CN102423468B CN102423468B CN 201110379598 CN201110379598A CN102423468B CN 102423468 B CN102423468 B CN 102423468B CN 201110379598 CN201110379598 CN 201110379598 CN 201110379598 A CN201110379598 A CN 201110379598A CN 102423468 B CN102423468 B CN 102423468B
- Authority
- CN
- China
- Prior art keywords
- hepatic fibrosis
- chinese medicinal
- chinese medicine
- medicine composition
- medicinal composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Chinese medicinal composition for resisting hepatic fibrosis and a preparation method and use thereof. The Chinese medicinal composition is prepared from the following Chinese medicinal materials: herb of virgate vormwood, white atractylodes rhizome, prepared aconite root, dried ginger, honey-fried licorice root and cinnamon, according to the mass ratio of 3:6:1.5:1.5:3:1. The Chinese medicinal composition is prepared through subjecting the Chinese medicinal materials, i.e. the herb of virgate vormwood, the white atractylodes rhizome, the prepared aconite root, the dried ginger, the honey-fried licorice root and the cinnamon to water decoction according to a matching ratio, extracting and concentrating. Proved by the pharmacodynamic tests, the Chinese medicinal composition disclosed by the invention can lower the serum transaminase of hepatic fibrosis model mice, can relieve the degree of the liver collagen deposition of the hepatic fibrosis model mice, can improve the hepatic inflammation and the fibrosis pathological change of the hepatic fibrosis model mice, and has the effect of resisting the pathological change of the hepatic fibrosis, so that the Chinese medicinal composition can be used for preparing a pharmaceutical preparation for resisting the hepatic fibrosis.
Description
Technical field
The present invention relates to Chinese medicine composition of a kind of anti-hepatic fibrosis and its preparation method and application, belong to technical field of Chinese medicines.
Background technology
Hepatic fibrosis is the common pathologic basis that various chronic hepatopathys are developed to liver cirrhosis, its essence is that liver inner cell epimatrix is synthetic unbalance with degraded, cause extracellular matrix especially collagen deposit in a large number at liver.The hepatic fibrosis sustainable development causes corresponding organ dysfunction and exhaustion, the serious harm life and health.Slow down, stop and even reverse hepatic fibrosis, to the generation that reduces severe complication, improve quality of life of patients and improve survival rate and be significant.Therefore, the medicine of development anti-hepatic fibrosis has obvious using value.
Hepatic fibrosis is a dynamic pathological process, a plurality of stages that comprise generation, develop and disappear, and each stage has a plurality of links to influence each other, therefore, only not ideal enough for the effect of single link treatment hepatic fibrosis.The Chinese medicine compound composition is various, has multipath, too many levels, multi-level comprehensive effect, and is evident in efficacy to the hepatic fibrosis of pathological changes complexity, and has broad application prospects.
Summary of the invention
One of technical problem to be solved by this invention is to provide a kind of Chinese medicine composition of anti-hepatic fibrosis, and two of technical problem to be solved is to provide the preparation method and application of described Chinese medicine composition.
In order to solve the problems of the technologies described above, the technical solution used in the present invention is as follows:
A kind of Chinese medicine composition of anti-hepatic fibrosis is characterized in that, is raw material by Chinese crude drug Herba Artemisiae Scopariae, the Rhizoma Atractylodis Macrocephalae, Radix Aconiti Lateralis Preparata, Rhizoma Zingiberis, Radix Glycyrrhizae Preparata, Cortex Cinnamomi, is 3: 6: 1.5 in mass ratio: be prepared from 1.5: 3: 1.
A kind of preparation method of Chinese medicine composition of described anti-hepatic fibrosis is to take at first in proportion Chinese crude drug Herba Artemisiae Scopariae, the Rhizoma Atractylodis Macrocephalae, Radix Aconiti Lateralis Preparata, Rhizoma Zingiberis, Radix Glycyrrhizae Preparata and Cortex Cinnamomi, and wherein Cortex Cinnamomi is removed the peel; Then water decocts 2 times together, and from each 1 hour of boiling timing, decoction for the first time was 10 times of total quality of medicinal material with water quality, and decoction for the second time is 8 times of total quality of medicinal material with water quality; Merge at last decoction liquor twice, concentrated being prepared from.
The pharmaceutical preparation that Chinese medicine composition of the present invention or described Chinese medicine composition and pharmaceutically acceptable pharmaceutical carrier can be applicable to prepare anti-hepatic fibrosis.
Described pharmaceutical preparation can be any pharmaceutically useful dosage form, and these dosage forms comprise: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch; The preferred oral dosage form, as: capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, unguentum etc.Described peroral dosage form can contain excipient commonly used, such as binding agent, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, can carry out coating to tablet in case of necessity.Suitable filler comprises cellulose, mannitol, lactose and other similar filler; Suitable disintegrating agent comprises starch, polyvinylpyrrolidone and starch derivatives, for example sodium starch glycollate; Suitable lubricant comprises, for example magnesium stearate; The acceptable wetting agent of suitable medicine comprises sodium lauryl sulphate.
Chinese medicine composition of the present invention is comprised of Herba Artemisiae Scopariae, the Rhizoma Atractylodis Macrocephalae, Radix Aconiti Lateralis Preparata, Rhizoma Zingiberis, Radix Glycyrrhizae Preparata, Cortex Cinnamomi.In the side, Herba Artemisiae Scopariae, Radix Aconiti Lateralis Preparata and Cortex Cinnamomi are share, using medicines of both cold and hot natures simultaneously, warming YANG jaundice eliminating; Rhizoma Zingiberis, the Rhizoma Atractylodis Macrocephalae, Radix Glycyrrhizae spleen invigorating warming middle-JIAO for eliminating dampness, full side cures mainly the YIN jaundice coldness of the body, deep-thready pulse, body such as dark yellow, normal urination person.
The present invention adopts carbon tetrachloride (carbon tetrachloride, the CCl of extensive use
4) the hepatic fibrosis in mice model of inducing, use Chinese medicine composition 6g crude drug of the present invention/kg gastric infusion, result shows, Chinese medicine composition of the present invention has the reduction serum aminotransferase activity to the Liver Fibrosis Model mice, can alleviate the deposition of collagen type Ⅰ degree, improve liver inflammatory and fibrosis pathology and change, the effect with anti-hepatic fibrosis pathological changes.
Description of drawings
Fig. 1 is that Chinese medicine composition of the present invention is to CCl
4The impact of the serum aminotransferase activity of Liver Fibrosis Model mice.
Fig. 2 is that Chinese medicine composition of the present invention is to CCl
4The impact of the hepatic tissue hydroxyproline of Liver Fibrosis Model mice.
Fig. 3 is that Chinese medicine composition of the present invention is to CCl
4The impact that the hepatic pathology of Liver Fibrosis Model mice changes.
Fig. 4 is that Chinese medicine composition of the present invention is to CCl
4The impact of the deposition of collagen type Ⅰ of Liver Fibrosis Model mice.
In figure: N-represents normal group; M-represents model control group; Y represents the Yinchen Shufu Decoction group; P-represents positive controls.
The specific embodiment
Below in conjunction with specific embodiments and the drawings, further set forth the present invention.These embodiment are interpreted as only being used for explanation the present invention rather than being used for restriction protection scope of the present invention.After the content of having read the present invention's record, those skilled in the art can make various changes or modifications the present invention, and these equivalences change and modification falls into claims limited range of the present invention equally.
Embodiment
Get Chinese crude drug Herba Artemisiae Scopariae 300 grams, the Rhizoma Atractylodis Macrocephalae 600 grams, Radix Aconiti Lateralis Preparata 150 grams, Rhizoma Zingiberis 150 grams, Radix Glycyrrhizae Preparata 300 grams and Cortex Cinnamomi (peeling) 100 grams, decocting boils 2 times, from each 1 hour of boiling timing, decocting for the first time with water quality is 16kg (be total quality of medicinal material 10 times), decocting for the second time with water quality is 12.8kg (be total quality of medicinal material 8 times), merge decoction liquor twice, simmer down to 2000mL concentrated solution.
Test example (anti-CCl
4The hepatic fibrosis mouse experiment)
Select 10 age in week male C57BL/6 mice, cleaning level is supplied with by Shanghai Slac Experimental Animal Co., Ltd..Mice is divided into normal group (N), model group (M), Yinchen Shufu Decoction group (Y) and positive drug group (P) at random.Except normal group (lumbar injection equivalent normal saline), all the other each groups are all with 10%CCl
4Olive oil solution 2ml/kg Mouse Weight lumbar injection is injected weekly 3 times, continuous 4 weeks.
From modeling, the Yinchen Shufu Decoction group gives Chinese medicine composition 6g crude drug of the present invention/kg body weight gavage, and the positive drug group gives N-acetyl-L-cysteine 0.15g/kg body weight gavage, and in totally 4 weeks, normal group and model group wait the capacity normal saline.Measure mice serum glutamate pyruvate transaminase, glutamic oxaloacetic transaminase, GOT activity and hepatic tissue hydroxyprolin levels after medication finishes, carry out hepatic tissue pathology dyeing and Picro-Sirius red chromoscopy.
Table 1 Chinese medicine composition of the present invention is to CCl
4The impact of hepatic fibrosis mice ALT, AST activity
| Group | n | ALT active (IU/L) | AST active (IU/L) |
| N | 10 | 106.14±31.72 ** | 145.11±42.34 ** |
| M | 10 | 191.72±44.24 | 232.55±58.11 |
| Y | 10 | 138.51±39.42 * | 159.74±42.37 ** |
| P | 10 | 169.30±51.41 | 189.82±66.70 |
Annotate: compare with model group,
*P＜0.05,
*P＜0.01.
Result of the test shows: Chinese medicine composition of the present invention can reduce mice serum glutamate pyruvate transaminase and glutamic oxaloacetic transaminase, GOT active (seeing Table 1 and shown in Figure 1), in figure:
*P＜0.05,
*P＜0.01vs model.Chinese medicine composition of the present invention also can reduce mouse liver hydroxyproline content (seeing Fig. 2).Hepatic tissue HE coloration result shows, model group visible portal area massive inflammatory cells infiltrated, a large amount of hypertrophy of fibroblast, the extensive degeneration of hepatocyte and necrosis; After Chinese medicine composition medication of the present invention, inflammatory cell infiltration and fibroblast proliferation obviously reduce, and hepatocellular degeneration and necrosis alleviate (seeing Fig. 3); Hepatic tissue Picro-Sirius red collagen staining result shows, the visible more pseudolobuli formation in model group portal area, a large amount of collagen fiber depositions; Chinese medicine composition group of the present invention has no pseudolobuli and forms, and the collagen fiber deposition alleviates (seeing Fig. 4).
To sum up experimental result shows: Chinese medicine composition of the present invention has the effect of anti-hepatic fibrosis pathological changes.
Claims (3)
1. the Chinese medicine composition of an anti-hepatic fibrosis is characterized in that: be raw material by Chinese crude drug Herba Artemisiae Scopariae, the Rhizoma Atractylodis Macrocephalae, Radix Aconiti Lateralis Preparata, Rhizoma Zingiberis, Radix Glycyrrhizae Preparata, Cortex Cinnamomi, and 3: 6: 1.5 in mass ratio: be prepared from 1.5: 3: 1.
2. the preparation method of the Chinese medicine composition of an anti-hepatic fibrosis claimed in claim 1, it is characterized in that: take at first in proportion Chinese crude drug Herba Artemisiae Scopariae, the Rhizoma Atractylodis Macrocephalae, Radix Aconiti Lateralis Preparata, Rhizoma Zingiberis, Radix Glycyrrhizae Preparata and Cortex Cinnamomi, wherein Cortex Cinnamomi is removed the peel; Then water decocts 2 times together, and from each 1 hour of boiling timing, decoction for the first time was 10 times of total quality of medicinal material with water quality, and decoction for the second time is 8 times of total quality of medicinal material with water quality; Merge at last decoction liquor twice, concentrated being prepared from.
3. Chinese medicine composition claimed in claim 1 or described Chinese medicine composition and the pharmaceutically acceptable pharmaceutical carrier application in the pharmaceutical preparation of preparation anti-hepatic fibrosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110379598 CN102423468B (en) | 2011-11-24 | 2011-11-24 | Chinese medicinal composition for resisting hepatic fibrosis and preparation method and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110379598 CN102423468B (en) | 2011-11-24 | 2011-11-24 | Chinese medicinal composition for resisting hepatic fibrosis and preparation method and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102423468A CN102423468A (en) | 2012-04-25 |
| CN102423468B true CN102423468B (en) | 2013-06-19 |
Family
ID=45957552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110379598 Active CN102423468B (en) | 2011-11-24 | 2011-11-24 | Chinese medicinal composition for resisting hepatic fibrosis and preparation method and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102423468B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111150826B (en) * | 2020-02-17 | 2021-11-09 | 河南中医药大学 | Traditional Chinese medicine for treating post-compensation hepatitis B cirrhosis |
| CN112891545B (en) * | 2021-03-12 | 2022-06-07 | 中国药科大学 | Anti-hepatic fibrosis composition and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101693094A (en) * | 2009-09-07 | 2010-04-14 | 湖南康普制药有限公司 | Traditional Chinese medicine compound preparation for treating viral hepatitis and complication |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101607011B (en) * | 2009-07-24 | 2011-06-22 | 崔延昌 | Traditional Chinese medicine for treating cholecystitis post-operative complacation |
-
2011
- 2011-11-24 CN CN 201110379598 patent/CN102423468B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101693094A (en) * | 2009-09-07 | 2010-04-14 | 湖南康普制药有限公司 | Traditional Chinese medicine compound preparation for treating viral hepatitis and complication |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102423468A (en) | 2012-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101002906A (en) | Compounding traditional Chinese medicine, and its use | |
| CN104069339A (en) | Traditional Chinese medicine composition for treating myasthenia gravis and preparation method thereof | |
| CN102670642B (en) | Traditional Chinese compound medicament for treating fatty liver disease | |
| CN102423468B (en) | Chinese medicinal composition for resisting hepatic fibrosis and preparation method and use thereof | |
| CN105125851A (en) | Traditional Chinese medicine treating 2-type diabetes and preparation technology | |
| CN102302544B (en) | Chinese medicinal composition for preventing and treating hepatic fibrosis | |
| CN103223069A (en) | Traditional Chinese medicine composition for treating hepatitis | |
| CN102429977B (en) | Medicine for treating diabetes | |
| CN100364601C (en) | Chinese traditional medicine composition for treating diabetic nephropathy | |
| CN104043045A (en) | Pharmaceutical composition for treating optic atrophy | |
| CN101036708A (en) | Medicine composition for treatment of cardio-cerebralvascular disease | |
| CN103285343B (en) | Medicine for treating liver cancer and preparation method thereof | |
| CN103239674B (en) | Antineoplastic traditional Chinese medicine composition and preparation method thereof | |
| CN103721228B (en) | A kind of Chinese medicine composition for the treatment of epistaxis and preparation method thereof | |
| CN104000871A (en) | Drug for treating myocardial ischemia | |
| CN102631430B (en) | Traditional Chinese medicine composition for resisting hepatic fibrosis, as well as preparation method and application thereof | |
| CN104547800A (en) | Use of traditional Chinese medicine preparation in preparation of medicine for treating alcoholic fatty liver | |
| CN101607070B (en) | Pharmaceutical composition for treating heart cerebrovascular disease | |
| CN106420901B (en) | A kind of herbal mixture for treating fatty liver | |
| CN104587281A (en) | Spleen invigoration and diuresis promoting traditional Chinese medicine composition for treating cirrhosis and preparation | |
| CN110368475A (en) | A kind of drug and preparation method thereof for malignant tumour early stage | |
| CN102357171A (en) | Traditional Chinese medicine composition for preventing and curing hepatic fibrosis, and preparation method and application thereof | |
| CN103494939A (en) | Traditional Chinese medicine for treating senile habitual constipation | |
| CN103705868B (en) | One treats hyperthyroid pharmaceutical composition and application thereof | |
| CN108295221B (en) | Traditional Chinese medicine composition for treating Parkinson's disease and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |